214 related articles for article (PubMed ID: 3504437)
21. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
Thiele J; Kvasnicka HM; Vardiman J
Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
[TBL] [Abstract][Full Text] [Related]
23. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
Thiele J; Kvasnicka HM
Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.
Thiele J; Kvasnicka HM; Orazi A
Semin Hematol; 2005 Oct; 42(4):184-95. PubMed ID: 16210032
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders.
Thiele J; Kvasnicka HM
Semin Thromb Hemost; 2006 Apr; 32(3):219-30. PubMed ID: 16673276
[TBL] [Abstract][Full Text] [Related]
26. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.
Florena AM; Tripodo C; Iannitto E; Porcasi R; Ingrao S; Franco V
Haematologica; 2004 Aug; 89(8):911-9. PubMed ID: 15339673
[TBL] [Abstract][Full Text] [Related]
27. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
Kvasnicka HM; Thiele J
Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
[TBL] [Abstract][Full Text] [Related]
28. Osteoclasts and bone remodeling in chronic myeloproliferative disorders. A histochemical and morphometric study on trephine biopsies in 165 patients.
Thiele J; Hoeppner B; Wienhold S; Schneider G; Fischer R; Zankovich R
Pathol Res Pract; 1989 Jun; 184(6):591-9. PubMed ID: 2780431
[TBL] [Abstract][Full Text] [Related]
29. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
30. [Primary thrombocythemia. A review of the literature and description of a clinical case].
Gambarova F
Minerva Med; 1990 Mar; 81(3 Suppl):53-63. PubMed ID: 2183087
[TBL] [Abstract][Full Text] [Related]
31. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
32. The myeloproliferative disorders. An historical appraisal and personal experiences.
Michiels JJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():1-14. PubMed ID: 8951768
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
[TBL] [Abstract][Full Text] [Related]
34. Chronic myeloproliferative disorders (CMPD).
Burkhardt R; Bartl R; Jäger K; Frisch B; Kettner G; Mahl G; Sund M
Pathol Res Pract; 1984 Nov; 179(2):131-86. PubMed ID: 6395125
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of bone marrow biopsy in essential thrombocythemia.
Annaloro C; Lambertenghi Deliliers G; Oriani A; Pozzoli E; Lambertenghi Deliliers D; Radaelli F; Faccini P
Haematologica; 1999 Jan; 84(1):17-21. PubMed ID: 10091388
[TBL] [Abstract][Full Text] [Related]
36. Primary (essential) thrombocythemia versus polycythemia vera rubra. A histomorphometric analysis of bone marrow features in trephine biopsies.
Thiele J; Zankovich R; Schneider G; Kremer B; Fischer R; Diehl V
Anal Quant Cytol Histol; 1988 Oct; 10(5):375-82. PubMed ID: 3207462
[TBL] [Abstract][Full Text] [Related]
37. Asymptomatic essential thrombocythemia: a case report.
Kapoor M; Misra V; Singh M; Mehrotra R; Dwivedi M
Indian J Pathol Microbiol; 2003 Oct; 46(4):655-7. PubMed ID: 15025370
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies.
Thiele J; Kvasnicka HM; Diehl V; Fischer R; Michiels J
Leuk Lymphoma; 1999 Apr; 33(3-4):207-18. PubMed ID: 10221501
[TBL] [Abstract][Full Text] [Related]
39. [Interferon therapy in essential thrombocythemia].
Seewann HL
Wien Med Wochenschr; 1993; 143(16-17):420-4. PubMed ID: 8273365
[TBL] [Abstract][Full Text] [Related]
40. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
